First Time Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy

Related

• 

  RGX-314 for Neovascular AMD: Ongoing Phase I/IIa Results for Cohorts 1-5

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2020

• 

  Episode 198: Journal Club about Online Physician Reviews, Systematic Review Reliability, SCORE2 24 month Data, Brolucizumab FDA Approval

  Jayanth Sridhar, MD

  Member Podcasts

  2019

• 

  Expert Panel: Socioeconomics

  Linda A. Lam, MD, MBA, FASRS

  Ella H Leung, MD

  Mohsin H. Ali, MD

  Hasenin Al-khersan, MD

  Miguel A. Busquets, MD, FACS

  Annual Meeting Talks

  2024